Payment overview · 2025
General Payments
$2,618.60
67 reported records · 14 companies
Healthcare provider profile · identity verified
Mark Richard Robbins, M.D.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · TYLER, TX · NPI 1891797429
Verified facts
What the public records show
CMS Open Payments records show Mark Richard Robbins, M.D. received $2,618.60 in general payments during 2025 across 67 reported records.
AngioDynamics, Inc. accounted for 66.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $1,748.38 | 66.8% | 33 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $168.84 | 6.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $137.55 | 5.2% | 4 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $125.99 | 4.8% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $98.95 | 3.8% | 3 | 2025 |
| Neuros Medical, Inc. | Unresolved — no canonical attribution shown | $92.47 | 3.5% | 5 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $64.48 | 2.5% | 3 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $56.93 | 2.2% | 5 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $39.87 | 1.5% | 2 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $23.89 | 0.9% | 1 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $16.72 | 0.6% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $16.11 | 0.6% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $14.76 | 0.6% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $13.66 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $1,600.00 | 1 |
| Food and Beverage | $1,018.60 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VENACURE 1470 PRO Normalized: venacure 1470 pro |
Device | AngioDynamics, Inc. | $1,620.94 | 2 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $168.84 | 3 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $115.08 | 3 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $107.29 | 29 | 2025 |
Source payment records
|
|||||
| Altius Normalized: altius |
Device | Neuros Medical, Inc. | $92.47 | 5 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $65.45 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $64.48 | 3 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $56.93 | 5 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $49.78 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| GORE PROPATEN Vascular Graft Normalized: gore propaten vascular graft |
Device | W. L. Gore & Associates, Inc. | $32.10 | 1 | 2025 |
Source payment records
|
|||||
| GORE-TEX Suture Normalized: gore tex suture |
Device | W. L. Gore & Associates, Inc. | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| R2P MISAGO Normalized: r2p misago |
Device | Terumo Medical Corporation | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $20.15 | 2 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Systems Undivided Normalized: igt devices systems undivided |
Device | Philips North America LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 228 | 79 |
| Cilostazol | Cilostazol | 55 | 13 |
| Xarelto | Rivaroxaban | 50 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 26 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,618.60 · 67 records | AngioDynamics, Inc. | ALPHAVAC, ARTEGRAFT VASCULAR GRAFT, AURYON LASER SYSTEM 100-120 VAC, Altius, CARDIVA VASCADE 6/7F VCS, CGuard Prime Carotid Stent System, ELUVIA, ENROUTE Transcarotid Neuroprotection System, ESPRIT, Flexitouch Plus, GORE PROPATEN Vascular Graft, GORE VIABAHN VBX Balloon Expandable Endo, GORE-TEX Suture, General - Vascular Intervention, IGT Devices Systems Undivided, LYMPHA PRESS OPTIMAL PLUS(US) BT, Nimbl, PCD-51 731A (US) - White, PCD-52 737A (US) White, R2P MISAGO, SUPERA, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VENACURE 1470 PRO, ZILVER PTX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error